Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Woohyeun | - |
dc.contributor.author | Kim, Jin-Seok | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Choi, Byoung Geol | - |
dc.contributor.author | Jang, Won Young | - |
dc.contributor.author | Kang, Dong Oh | - |
dc.contributor.author | Park, Yoonjee | - |
dc.contributor.author | Choi, Jah Yeon | - |
dc.contributor.author | Roh, Seung-Young | - |
dc.contributor.author | Na, Jin Oh | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Kim, Eung Ju | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Seo, Hong Seog | - |
dc.contributor.author | Choi, Se Yeon | - |
dc.contributor.author | Byun, Jae Kyeong | - |
dc.contributor.author | Cha, Jinah | - |
dc.contributor.author | Oh, Dong Joo | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.date.accessioned | 2021-08-30T15:12:30Z | - |
dc.date.available | 2021-08-30T15:12:30Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 0910-8327 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53277 | - |
dc.description.abstract | Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients. We compared the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAT) with potent P2Y12 inhibitor-based DAPT in Korean patients. A total of 4152 AMI patients who underwent percutaneous coronary intervention (PCI) in the Korea Acute Myocardial Infarction Registry were analyzed retrospectively. Patients were divided into two groups: the TAT group (aspirin + clopidogrel + cilostazol,n = 3161) and the potent DAPT group (aspirin + potent P2Y12 inhibitors [ticagrelor or prasugrel],n = 991). Major clinical outcomes at 30 days and 2 years were compared between the two groups using propensity score matching (PSM) analysis. After PSM (869 pairs), there were no significant differences between the two groups in the incidence of total death, cardiac death, myocardial infarction (MI), target vessel revascularization, stent thrombosis, and stroke at 30 days and 2 years. However, the Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding rates were significantly lower in the TAT group compared with the potent DAPT group at 2 years (6.4% vs. 3.6%,p = 0.006). In Korean AMI patients undergoing PCI, TAT with cilostazol was associated with lower bleeding than the potent P2Y12 inhibitor-based DAPT without increased ischemic risk. These results could provide a rationale for the use of TAT in East Asian AMI patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | ELUTING STENT IMPLANTATION | - |
dc.subject | MULTICENTER RANDOMIZED-TRIAL | - |
dc.subject | REDUCES LATE RESTENOSIS | - |
dc.subject | CLINICAL-OUTCOMES | - |
dc.subject | ARTERY-DISEASE | - |
dc.subject | FOCUSED UPDATE | - |
dc.subject | HEART-DISEASE | - |
dc.subject | CLOPIDOGREL | - |
dc.subject | LONG | - |
dc.subject | EFFICACY | - |
dc.title | Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jin-Seok | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.contributor.affiliatedAuthor | Na, Jin Oh | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Ung | - |
dc.contributor.affiliatedAuthor | Kim, Eung Ju | - |
dc.contributor.affiliatedAuthor | Seo, Hong Seog | - |
dc.identifier.doi | 10.1007/s00380-020-01598-w | - |
dc.identifier.wosid | 000554756000001 | - |
dc.identifier.bibliographicCitation | HEART AND VESSELS, v.35, no.9, pp.1181 - 1192 | - |
dc.relation.isPartOf | HEART AND VESSELS | - |
dc.citation.title | HEART AND VESSELS | - |
dc.citation.volume | 35 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1181 | - |
dc.citation.endPage | 1192 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | ELUTING STENT IMPLANTATION | - |
dc.subject.keywordPlus | MULTICENTER RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | REDUCES LATE RESTENOSIS | - |
dc.subject.keywordPlus | CLINICAL-OUTCOMES | - |
dc.subject.keywordPlus | ARTERY-DISEASE | - |
dc.subject.keywordPlus | FOCUSED UPDATE | - |
dc.subject.keywordPlus | HEART-DISEASE | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | LONG | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | Cilostazol | - |
dc.subject.keywordAuthor | Antiplatelet therapy | - |
dc.subject.keywordAuthor | Acute myocardial infarction | - |
dc.subject.keywordAuthor | Percutaneous coronary intervention | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.